Filing Overview
HealthCor Catalio Acquisition Corp. filed this Form 8-K on December 21, 2021, reporting results of its extraordinary general meeting and related events concerning its proposed business combination with Hyperfine, Inc. and Liminal Sciences, Inc. The transaction was expected to close on December 22, 2021, subject to remaining conditions, with the combined company’s Class A common stock expected to begin trading on Nasdaq under “HYPR” on December 23, 2021.
Key Financial and Transaction Metrics
- 17,491,773 ordinary shares were present or represented at the meeting, equal to 66.03% of voting power and sufficient to establish a quorum.
- 17,142,244 Class A ordinary shares were redeemed for approximately $10.00 per share, representing aggregate redemptions of approximately $171.4 million.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity balance, or operating guidance figures.
Shareholder Vote and Material Changes
- Shareholders approved the Business Combination Proposal, Domestication Proposal, Organizational Documents Proposal, Advisory Charter Proposals 4A through 4I, Stock Issuance Proposal, Director Election Proposal, and Incentive Plan Proposal.
- The Business Combination Proposal received 16,165,494 votes for, 1,325,650 against, and 629 abstentions.
- The Stock Issuance Proposal received 15,030,667 votes for, 2,460,166 against, and 940 abstentions.
- The Incentive Plan Proposal received 15,155,014 votes for, 2,335,743 against, and 1,016 abstentions.
- The Director Election Proposal received 5,175,000 votes for, with no votes against or abstentions.
- The proposed transactions were authorized but remained subject to satisfaction or waiver of other closing conditions. The adjournment proposal was not presented because sufficient votes had been obtained.
Outlook, Risks, and Unusual Items
- Management expected completion of the business combination on December 22, 2021 and Nasdaq trading under “HYPR” on December 23, 2021; these were forward-looking expectations, not confirmed completion events in this filing.
- Key risks include failure to satisfy closing conditions or complete related PIPE financing, termination of the merger agreement, inability to maintain Nasdaq listing, transaction disruption and costs, and failure to realize anticipated benefits.
- Additional risks include product development and commercialization of the Swoop system, regulatory clearances, market acceptance, reimbursement and pricing, competition, supply and licensing arrangements, financing needs, future revenue and expense estimates, employee retention, COVID-19 effects, and the ability to grow profitably.
- The approximately $171.4 million redemption represents a significant reduction in the SPAC’s cash proceeds and should be considered when assessing post-transaction liquidity and financing requirements.
Facts Investors Should Verify
- Whether the business combination and domestication actually closed on December 22, 2021 and whether all closing conditions were satisfied.
- The final number of shares outstanding, proceeds retained after redemptions, and terms and completion status of any PIPE financing.
- Whether the combined company began trading under “HYPR” and maintained Nasdaq listing.
- Hyperfine’s post-combination revenue, cash burn, liquidity, debt, operating losses, and capital requirements, which are not provided in this filing.
- The regulatory status, commercialization progress, adoption, reimbursement, and manufacturing or supply arrangements for the Swoop system and other products.